Zacks Investment Research downgraded shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) from a hold rating to a sell rating in a research report sent to investors on Thursday, July 13th.
According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “
A number of other analysts have also weighed in on FLXN. Royal Bank Of Canada set a $44.00 price objective on shares of Flexion Therapeutics and gave the stock a buy rating in a research note on Sunday, March 26th. Janney Montgomery Scott reissued a buy rating and issued a $35.00 price target (up previously from $30.00) on shares of Flexion Therapeutics in a research note on Wednesday, July 12th. Cantor Fitzgerald reissued an overweight rating and set a $34.00 price objective on shares of Flexion Therapeutics in a research report on Saturday, March 25th. BMO Capital Markets reaffirmed a buy rating on shares of Flexion Therapeutics in a report on Tuesday, June 27th. Finally, Wells Fargo & Company restated an outperform rating and issued a $30.00 price objective on shares of Flexion Therapeutics in a research report on Saturday, March 25th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $31.10.
Shares of Flexion Therapeutics (FLXN) traded up 1.02% during trading on Thursday, hitting $23.82. The stock had a trading volume of 403,405 shares. The firm has a 50-day moving average of $20.08 and a 200 day moving average of $20.83. The company’s market capitalization is $756.45 million. Flexion Therapeutics has a 1-year low of $15.44 and a 1-year high of $29.41.
Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.73) by $0.02. Equities research analysts predict that Flexion Therapeutics will post ($3.56) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Flexion Therapeutics, Inc. (FLXN) Downgraded to Sell at Zacks Investment Research” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://sportsperspectives.com/2017/07/24/flexion-therapeutics-inc-flxn-rating-lowered-to-sell-at-zacks-investment-research-2-updated.html.
In related news, Director Mark Stejbach purchased 1,580 shares of Flexion Therapeutics stock in a transaction on Friday, June 16th. The stock was bought at an average price of $17.02 per share, with a total value of $26,891.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael D. Clayman purchased 5,000 shares of Flexion Therapeutics stock in a transaction on Monday, June 5th. The stock was bought at an average cost of $17.23 per share, with a total value of $86,150.00. Following the transaction, the insider now directly owns 20,146 shares of the company’s stock, valued at $347,115.58. The disclosure for this purchase can be found here. Insiders own 15.98% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in FLXN. Bank of New York Mellon Corp raised its stake in Flexion Therapeutics by 9.0% in the first quarter. Bank of New York Mellon Corp now owns 2,124,208 shares of the specialty pharmaceutical company’s stock worth $57,163,000 after buying an additional 175,879 shares during the period. Vanguard Group Inc. raised its stake in Flexion Therapeutics by 3.4% in the first quarter. Vanguard Group Inc. now owns 995,321 shares of the specialty pharmaceutical company’s stock worth $26,784,000 after buying an additional 32,479 shares during the period. State Street Corp increased its position in Flexion Therapeutics by 111.8% in the first quarter. State Street Corp now owns 829,254 shares of the specialty pharmaceutical company’s stock valued at $22,316,000 after buying an additional 437,648 shares in the last quarter. Driehaus Capital Management LLC increased its position in Flexion Therapeutics by 16.3% in the first quarter. Driehaus Capital Management LLC now owns 523,060 shares of the specialty pharmaceutical company’s stock valued at $14,076,000 after buying an additional 73,353 shares in the last quarter. Finally, Pictet Asset Management Ltd. purchased a new position in Flexion Therapeutics during the first quarter valued at about $7,323,000. Institutional investors and hedge funds own 75.16% of the company’s stock.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.